FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3181157775> ?p ?o ?g. }

• W3181157775 endingPage "1023" @default.
• W3181157775 startingPage "1011" @default.
• W3181157775 abstract "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by an immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLNs. A low dose of I-R-F induces not only high titers of long-lasting neutralizing antibodies (NAbs) but also more comprehensive T cell responses than RBD. Notably, I-R-F provides comprehensive protection in the form of a one-dose vaccine without an adjuvant. Our study shows that the pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques. Based on these promising results, we have initiated a randomized, placebo-controlled, phase I/II trial of the human I-P-R-F vaccine (V-01) in 180 healthy adults, and the vaccine appears safe and elicits strong antiviral immune responses. Due to its potency and safety, this engineered vaccine may become a next-generation vaccine candidate in the global effort to overcome COVID-19." @default.
• W3181157775 created "2021-07-19" @default.
• W3181157775 creator A5002590827 @default.
• W3181157775 creator A5006379107 @default.
• W3181157775 creator A5010051491 @default.
• W3181157775 creator A5010645599 @default.
• W3181157775 creator A5012718037 @default.
• W3181157775 creator A5013798522 @default.
• W3181157775 creator A5021420948 @default.
• W3181157775 creator A5022348147 @default.
• W3181157775 creator A5023693252 @default.
• W3181157775 creator A5026828654 @default.
• W3181157775 creator A5030068217 @default.
• W3181157775 creator A5032028363 @default.
• W3181157775 creator A5035676180 @default.
• W3181157775 creator A5038329314 @default.
• W3181157775 creator A5044089544 @default.
• W3181157775 creator A5049440121 @default.
• W3181157775 creator A5057527087 @default.
• W3181157775 creator A5057734030 @default.
• W3181157775 creator A5057980496 @default.
• W3181157775 creator A5061224519 @default.
• W3181157775 creator A5068512850 @default.
• W3181157775 creator A5071023760 @default.
• W3181157775 creator A5076498328 @default.
• W3181157775 creator A5076567651 @default.
• W3181157775 creator A5077132925 @default.
• W3181157775 creator A5084548257 @default.
• W3181157775 date "2021-07-15" @default.
• W3181157775 modified "2023-10-17" @default.
• W3181157775 title "Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2" @default.
• W3181157775 cites W1653912017 @default.
• W3181157775 cites W1667435701 @default.
• W3181157775 cites W1973196190 @default.
• W3181157775 cites W1976150116 @default.
• W3181157775 cites W1981029495 @default.
• W3181157775 cites W1982752226 @default.
• W3181157775 cites W1999498885 @default.
• W3181157775 cites W2034360108 @default.
• W3181157775 cites W2035671081 @default.
• W3181157775 cites W2041647537 @default.
• W3181157775 cites W2044389879 @default.
• W3181157775 cites W2076397065 @default.
• W3181157775 cites W2078397942 @default.
• W3181157775 cites W2095633747 @default.
• W3181157775 cites W2105667065 @default.
• W3181157775 cites W2106731348 @default.
• W3181157775 cites W2129302556 @default.
• W3181157775 cites W2151847720 @default.
• W3181157775 cites W2417798839 @default.
• W3181157775 cites W2562970611 @default.
• W3181157775 cites W2898668089 @default.
• W3181157775 cites W2971050087 @default.
• W3181157775 cites W3001897055 @default.
• W3181157775 cites W3004280078 @default.
• W3181157775 cites W3012650581 @default.
• W3181157775 cites W3013985547 @default.
• W3181157775 cites W3022917947 @default.
• W3181157775 cites W3024602798 @default.
• W3181157775 cites W3027204812 @default.
• W3181157775 cites W3034173374 @default.
• W3181157775 cites W3037923073 @default.
• W3181157775 cites W3042383115 @default.
• W3181157775 cites W3042833857 @default.
• W3181157775 cites W3043722389 @default.
• W3181157775 cites W3045578670 @default.
• W3181157775 cites W3045724532 @default.
• W3181157775 cites W3046061621 @default.
• W3181157775 cites W3048446898 @default.
• W3181157775 cites W3048620154 @default.
• W3181157775 cites W3083773456 @default.
• W3181157775 cites W3085586916 @default.
• W3181157775 cites W3087083211 @default.
• W3181157775 cites W3090679753 @default.
• W3181157775 cites W3092403777 @default.
• W3181157775 cites W3093367571 @default.
• W3181157775 cites W3094009122 @default.
• W3181157775 cites W3094860119 @default.
• W3181157775 cites W3102328262 @default.
• W3181157775 cites W3108693782 @default.
• W3181157775 cites W3109969518 @default.
• W3181157775 cites W3123053754 @default.
• W3181157775 cites W3137864390 @default.
• W3181157775 cites W69974816 @default.
• W3181157775 doi "https://doi.org/10.1038/s41422-021-00531-8" @default.
• W3181157775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8280646" @default.
• W3181157775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34267349" @default.
• W3181157775 hasPublicationYear "2021" @default.
• W3181157775 type Work @default.
• W3181157775 sameAs 3181157775 @default.
• W3181157775 citedByCount "37" @default.
• W3181157775 countsByYear W31811577752021 @default.
• W3181157775 countsByYear W31811577752022 @default.
• W3181157775 countsByYear W31811577752023 @default.
• W3181157775 crossrefType "journal-article" @default.
• W3181157775 hasAuthorship W3181157775A5002590827 @default.
• W3181157775 hasAuthorship W3181157775A5006379107 @default.
• W3181157775 hasAuthorship W3181157775A5010051491 @default.

• next